The strength of this study is the inclusion of a large number of patients who received bevacizumab and no other anti-VEGF therapy for wet AMD, with detailed registration of comorbidities and socioeconomic data, which enabled suitable matching and multivariate analysis. The gene discussed is VEGFA; the disease is wet macular degeneration.